Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.31 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.30 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11399787 | 0.83 | C1R (0.35) | LMNAALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL33832 | 0.77 | TDP1 (0.46) | ALDH1A1MEN1KMT2ATSHRTDP1 | |
| SCHEMBL7136437 | 0.77 | TDP1 (0.46) | ALDH1A1MEN1KMT2ATSHRTDP1 | |
| SCHEMBL2075135 | 0.75 | MAPT (0.36) | LMNAALDH1A1MEN1KMT2AHTT | |
| SCHEMBL3042315 | 0.75 | GPR35 (0.42) | LMNAALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL455622 | 0.75 | ALDH1A1 (0.48) | LMNAALDH1A1TSHRTDP1 | |
| SCHEMBL1179579 | 0.75 | PDE7A (0.35) | LMNAALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL6129444 | 0.75 | SMN1; SMN2 (0.38) | LMNAALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL7907935 | 0.75 | LMNA (0.33) | LMNAALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL1179476 | 0.75 | HPGD (0.38) | LMNAALDH1A1KMT2AHTTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9782428-B2 | Method for generation of broadly neutralizing anti-pathogen antibodies | NORTHEASTERN UNIVERSITY (US) | 2017-10-10 | — | — | US | claimed |
| US-7501438-B2 | Pyridoimidazole derivatives | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-03-10 | — | — | US | claimed |
| US-20080009491-A1 | 1-(3-naphthalen-1-yl-imidazo[1,5-a]pyridin-1-yl)-butan-1-one; chronic pain, an inflammatory disorder, rheumatoid arthritis, multiple sclerosis, osteoporosis and osteoarthritis; cannabinoid receptor ligands | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-01-10 | — | — | US | claimed |
| WO-2008005908-A2 | PYRIDOIMIDAZOLE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-01-10 | — | — | WO | claimed |
| EP-2900645-B1 | HERBICIDAL AND FUNGICIDAL 3-PHENYLISOXAZOLIN DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2019-08-21 | — | — | EP | disclosed |
| US-20180237487-A1 | LECTIN COMPOSITIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE TO AN ANTIGEN | OPSANITX LLC (US) | 2018-08-23 | — | — | US | disclosed |
| US-9951113-B2 | Lectin compositions and methods for modulating an immune response to an antigen | OPSANITX LLC (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170088595-A1 | LECTIN COMPOSITIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE TO AN ANTIGEN | GENITRIX, LLC | 2017-03-30 | — | — | US | disclosed |
| US-9597394-B2 | Lectin compositions and methods for modulating an immune response to an antigen | OPSANITX LLC (US) | 2017-03-21 | — | — | US | disclosed |
| US-9585392-B2 | 3-phenylisoxazolin derivatives with herbicidal action | BAYER CROPSCIENCE AG (DE) | 2017-03-07 | — | — | US | disclosed |
| US-20150297715-A1 | LECTIN COMPOSITIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE TO AN ANTIGEN | GENITRIX, LLC | 2015-10-22 | — | — | US | disclosed |
| US-20150245615-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | BAYER CROPSCIENCE AG (DE) | 2015-09-03 | — | — | US | disclosed |
| US-5070013-A | IMMUNOCHEMICAL ASSAY FOR HUMAN GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR | SCHERING CORPORATION (US) | 1991-12-03 | — | — | US | disclosed |
| EP-0422037-A1 | IMMUNOCHEMICAL ASSAY FOR HUMAN GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR | Schering Biotech Corporation (US) | 1991-04-17 | — | — | EP | disclosed |
| WO-1990011782-A2 | IMMUNOCONJUGATES AND PRODRUGS AND THEIR USE IN ASSOCIATION FOR DRUG DELIVERY | CELLTECH LIMITED (GB) | 1990-10-18 | — | — | WO | disclosed |
| EP-0392745-A2 | Immunoconjugates and prodrugs and their use in association for drug delivery | CELLTECH LIMITED (GB) | 1990-10-17 | — | — | EP | disclosed |
| EP-0347078-A1 | Hybrid proteins | CELLTECH LIMITED (GB) | 1989-12-20 | — | — | EP | disclosed |
| WO-1989012108-A1 | IMMUNOCHEMICAL ASSAY FOR HUMAN GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR | SCHERING BIOTECH CORPORATION (US) | 1989-12-14 | — | — | WO | disclosed |
| WO-1989012098-A1 | HYBRID PROTEINS | CELLTECH LIMITED (GB) | 1989-12-14 | — | — | WO | disclosed |
| EP-0344957-A1 | Immunochemical assay for human granulocyte-macrophage colony stimulating factor | Schering Biotech Corporation (US) | 1989-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009491-A1 | 1-(3-naphthalen-1-yl-imidazo[1,5-a]pyridin-1-yl)-butan-1-one; chronic pain, an inflammatory disorder, rheumatoid arthritis, multiple sclerosis, osteoporosis and osteoarthritis; cannabinoid receptor ligands | CNR1, CNR2, OPRK1 | LMNA 1832/4885ALDH1A1 3016/4885MEN1 1588/4885 |
| US-20150245615-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | CYP4X1, CBR3, PAOX | LMNA 2676/4885ALDH1A1 1019/4885MEN1 4770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.